ANI Continues To Spearhead FDA’s CGT Path With Prucalopride Launch
US-Based Firm’s Novitium Pharma Subsidiary Holds 20 CGT Approvals
ANI Pharmaceuticals will compete with a product bringing in annual sales of more than $150m after launching the first generic with 180-day exclusivity via the FDA’s competitive generic therapy pathway.
